Free Trial

Edwards Lifesciences (EW) Competitors

Edwards Lifesciences logo
$107.16 +1.36 (+1.29%)
Closing price 11/13/2026 03:59 PM Eastern
Extended Trading
$106.84 -0.33 (-0.30%)
As of 11/13/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

EW vs. HSIC, AMN, ABT, ISRG, and MDT

Should you buy Edwards Lifesciences stock or one of its competitors? Edwards Lifesciences's main competitors and comparable companies include Henry Schein (HSIC), AMN Healthcare Services (AMN), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), and Medtronic (MDT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Edwards Lifesciences compare to Henry Schein?

Edwards Lifesciences (NYSE:EW) and Henry Schein (NASDAQ:HSIC) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

In the previous week, Edwards Lifesciences had 29 more articles in the media than Henry Schein. MarketBeat recorded 30 mentions for Edwards Lifesciences and 1 mentions for Henry Schein. Edwards Lifesciences' average media sentiment score of 0.64 beat Henry Schein's score of 0.60 indicating that Edwards Lifesciences is being referred to more favorably in the media.

Company Overall Sentiment
Edwards Lifesciences Positive
Henry Schein Positive

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 96.6% of Henry Schein shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by insiders. Comparatively, 0.9% of Henry Schein shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Edwards Lifesciences has a net margin of 15.30% compared to Henry Schein's net margin of 3.07%. Henry Schein's return on equity of 16.39% beat Edwards Lifesciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Edwards Lifesciences15.30% 16.06% 12.36%
Henry Schein 3.07%16.39%5.58%

Edwards Lifesciences has higher earnings, but lower revenue than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$6.67B9.23$1.07B$1.7760.54
Henry Schein$13.73B0.69$398M$3.6523.62

Edwards Lifesciences presently has a consensus price target of $109.56, suggesting a potential upside of 2.24%. Henry Schein has a consensus price target of $93.57, suggesting a potential upside of 8.53%. Given Henry Schein's higher probable upside, analysts plainly believe Henry Schein is more favorable than Edwards Lifesciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edwards Lifesciences
0 Sell rating(s)
3 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.88
Henry Schein
1 Sell rating(s)
5 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.50

Edwards Lifesciences has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Henry Schein has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Summary

Edwards Lifesciences beats Henry Schein on 9 of the 16 factors compared between the two stocks.

How does Edwards Lifesciences compare to AMN Healthcare Services?

Edwards Lifesciences (NYSE:EW) and AMN Healthcare Services (NYSE:AMN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Edwards Lifesciences has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

In the previous week, Edwards Lifesciences had 20 more articles in the media than AMN Healthcare Services. MarketBeat recorded 30 mentions for Edwards Lifesciences and 10 mentions for AMN Healthcare Services. Edwards Lifesciences' average media sentiment score of 0.64 beat AMN Healthcare Services' score of 0.55 indicating that Edwards Lifesciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edwards Lifesciences
15 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
AMN Healthcare Services
2 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Edwards Lifesciences has a net margin of 15.30% compared to AMN Healthcare Services' net margin of 3.10%. AMN Healthcare Services' return on equity of 23.42% beat Edwards Lifesciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Edwards Lifesciences15.30% 16.06% 12.36%
AMN Healthcare Services 3.10%23.42%7.19%

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Edwards Lifesciences currently has a consensus target price of $109.56, indicating a potential upside of 2.24%. AMN Healthcare Services has a consensus target price of $39.17, indicating a potential upside of 2.94%. Given AMN Healthcare Services' higher possible upside, analysts plainly believe AMN Healthcare Services is more favorable than Edwards Lifesciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edwards Lifesciences
0 Sell rating(s)
3 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.88
AMN Healthcare Services
1 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33

Edwards Lifesciences has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$6.67B9.23$1.07B$1.7760.54
AMN Healthcare Services$2.73B0.54-$95.70M$2.7513.84

Summary

Edwards Lifesciences beats AMN Healthcare Services on 11 of the 16 factors compared between the two stocks.

How does Edwards Lifesciences compare to Abbott Laboratories?

Abbott Laboratories (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Abbott Laboratories has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Abbott Laboratories has higher revenue and earnings than Edwards Lifesciences. Abbott Laboratories is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$44.33B4.24$6.52B$2.6840.52
Edwards Lifesciences$6.67B9.23$1.07B$1.7760.54

In the previous week, Edwards Lifesciences had 3 more articles in the media than Abbott Laboratories. MarketBeat recorded 30 mentions for Edwards Lifesciences and 27 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.27 beat Edwards Lifesciences' score of 0.64 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abbott Laboratories
21 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Edwards Lifesciences
15 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Abbott Laboratories presently has a consensus target price of $118.32, indicating a potential upside of 8.96%. Edwards Lifesciences has a consensus target price of $109.56, indicating a potential upside of 2.24%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, research analysts clearly believe Abbott Laboratories is more favorable than Edwards Lifesciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abbott Laboratories
0 Sell rating(s)
5 Hold rating(s)
21 Buy rating(s)
2 Strong Buy rating(s)
2.89
Edwards Lifesciences
0 Sell rating(s)
3 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.88

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.3% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Edwards Lifesciences has a net margin of 15.30% compared to Abbott Laboratories' net margin of 9.75%. Abbott Laboratories' return on equity of 18.04% beat Edwards Lifesciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Abbott Laboratories9.75% 18.04% 9.09%
Edwards Lifesciences 15.30%16.06%12.36%

Summary

Abbott Laboratories beats Edwards Lifesciences on 9 of the 17 factors compared between the two stocks.

How does Edwards Lifesciences compare to Intuitive Surgical?

Intuitive Surgical (NASDAQ:ISRG) and Edwards Lifesciences (NYSE:EW) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Intuitive Surgical has higher revenue and earnings than Edwards Lifesciences. Intuitive Surgical is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$10.06B15.28$2.86B$8.2753.64
Edwards Lifesciences$6.67B9.23$1.07B$1.7760.54

Intuitive Surgical has a net margin of 25.54% compared to Edwards Lifesciences' net margin of 15.30%. Intuitive Surgical's return on equity of 18.17% beat Edwards Lifesciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Intuitive Surgical25.54% 18.17% 15.73%
Edwards Lifesciences 15.30%16.06%12.36%

Intuitive Surgical presently has a consensus price target of $493.54, suggesting a potential upside of 11.26%. Edwards Lifesciences has a consensus price target of $109.56, suggesting a potential upside of 2.24%. Given Intuitive Surgical's higher possible upside, research analysts clearly believe Intuitive Surgical is more favorable than Edwards Lifesciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intuitive Surgical
1 Sell rating(s)
5 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.80
Edwards Lifesciences
0 Sell rating(s)
3 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.88

83.6% of Intuitive Surgical shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 0.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 0.3% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Intuitive Surgical has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

In the previous week, Intuitive Surgical had 4 more articles in the media than Edwards Lifesciences. MarketBeat recorded 34 mentions for Intuitive Surgical and 30 mentions for Edwards Lifesciences. Intuitive Surgical's average media sentiment score of 1.12 beat Edwards Lifesciences' score of 0.64 indicating that Intuitive Surgical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Intuitive Surgical
23 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Edwards Lifesciences
15 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Intuitive Surgical beats Edwards Lifesciences on 14 of the 16 factors compared between the two stocks.

How does Edwards Lifesciences compare to Medtronic?

Edwards Lifesciences (NYSE:EW) and Medtronic (NYSE:MDT) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by company insiders. Comparatively, 0.3% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Edwards Lifesciences has a net margin of 15.30% compared to Medtronic's net margin of 13.93%. Edwards Lifesciences' return on equity of 16.06% beat Medtronic's return on equity.

Company Net Margins Return on Equity Return on Assets
Edwards Lifesciences15.30% 16.06% 12.36%
Medtronic 13.93%14.78%7.97%

Edwards Lifesciences has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Edwards Lifesciences currently has a consensus price target of $109.56, indicating a potential upside of 2.24%. Medtronic has a consensus price target of $102.88, indicating a potential upside of 0.04%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Edwards Lifesciences is more favorable than Medtronic.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edwards Lifesciences
0 Sell rating(s)
3 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.88
Medtronic
1 Sell rating(s)
9 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.61

Medtronic has higher revenue and earnings than Edwards Lifesciences. Medtronic is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$6.67B9.23$1.07B$1.7760.54
Medtronic$36.36B3.62$4.80B$4.0625.33

In the previous week, Edwards Lifesciences had 9 more articles in the media than Medtronic. MarketBeat recorded 30 mentions for Edwards Lifesciences and 21 mentions for Medtronic. Medtronic's average media sentiment score of 0.85 beat Edwards Lifesciences' score of 0.64 indicating that Medtronic is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edwards Lifesciences
15 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Medtronic
15 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Edwards Lifesciences beats Medtronic on 11 of the 16 factors compared between the two stocks.

Get Edwards Lifesciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EW vs. The Competition

MetricEdwards LifesciencesHealthcare Equipment & Supplies IndustryHealthcare SectorNYSE Exchange
Market Cap$60.84B$5.98B$7.87B$23.49B
Dividend YieldN/A1.68%2.46%3.78%
P/E Ratio60.5439.3334.5629.82
Price / Sales9.235.548.333.50
Price / Cash37.1023.9521.9315.51
Price / Book5.624.454.353.72
Net Income$1.07B$143.92M$3.52B$1.08B
7 Day Performance5.15%-1.14%-1.52%0.58%
1 Month Performance21.71%-2.38%-3.54%-0.31%
1 Year Performance24.10%1.91%1.45%7.30%

Edwards Lifesciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EW
Edwards Lifesciences
2.4724 of 5 stars
$107.16
+1.3%
$109.56
+2.2%
N/A$60.84B$6.67B60.5416,000
HSIC
Henry Schein
2.3785 of 5 stars
$88.41
+2.7%
$93.57
+5.8%
N/A$9.75B$13.18B24.2225,000
AMN
AMN Healthcare Services
1.9865 of 5 stars
$38.00
+5.0%
$39.17
+3.1%
N/A$1.85B$2.73B13.722,664
ABT
Abbott Laboratories
4.2972 of 5 stars
$110.41
+0.4%
$118.32
+7.2%
N/A$199.88B$44.33B21.47115,000
ISRG
Intuitive Surgical
3.8227 of 5 stars
$460.56
+1.7%
$493.54
+7.2%
N/A$167.12B$10.06B54.0517,021

Related Companies and Tools


This page (NYSE:EW) was last updated on 11/15/2026 by MarketBeat.com Staff.
From Our Partners